Molluscum Contagiosum
VIDEO: Surge in molluscum contagiosum therapy approvals represents paradigm shift
MIAMI BEACH, Fla. — The recent FDA approvals of two treatments for molluscum contagiosum may represent a shift in how clinicians view this disease, according to a speaker at Masters of Pediatric Dermatology.
Boy in Okinawa presents with painful, itchy sore near his eye
The following case, provided by Michael Cater, MD, a pediatrician at Children’s Hospital of Orange County, California, is the first of a two-part series.
FDA approves Zelsuvmi for molluscum contagiosum
Topical Zelsuvmi has been approved by the FDA for use in patients aged 1 year and older with molluscum contagiosum, Ligand Pharmaceuticals announced in a press release.
Top in dermatology: Therapies for basal cell carcinoma, molluscum contagiosum show promise
Early data from a phase 1/2 trial showed promising results for AIV001, AiViva Biopharma’s intradermal basal cell carcinoma treatment, according to a company press release.
Aesthetic approvals top Healio Dermatology FDA news in 2023
The FDA approved multiple products for dermatologic indications this year.
Japanese trial shows TO-208 efficacious in molluscum contagiosum
Torii Pharmaceutical Co. Ltd. has reported positive top-line results for a phase 3 trial evaluating TO-208 for the treatment of molluscum contagiosum in Japan, Verrica Pharmaceuticals announced in a press release.
Verrica reports net loss of $24.8 million in third quarter of 2023
Verrica reported a net loss of $24.8 million, or $0.54 per share in the third quarter of 2023, according to a press release. The company had a net income of $83,000 in the same period last year.